Renal cell carcinoma unclassified with medullary phenotype: a report of 2 cases and literature review
10.3969/j.issn.1009-8291.2024.12.007
- VernacularTitle:具髓质表型的未分类肾细胞癌2例报告并文献复习
- Author:
Yijun QIAN
1
;
Xiaohua LIU
2
;
Manming CAO
3
;
Wei DU
1
;
Kai GUO
1
;
Yawen XU
1
Author Information
1. Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280
2. Shayuan Street Community Health Service Center, Haizhu District, Guangzhou 510280
3. Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China
- Publication Type:Journal Article
- Keywords:
renal medullary carcinoma;
sickle cell trait;
SMARCB1;
unclassified renal cancer;
chemotherapy
- From:
Journal of Modern Urology
2024;29(12):1060-1063
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To investigate the clinical features and treatment of renal cell carcinoma unclassified with medullary phenotype (RCCU-MP), so as to improve the clinical understanding of this disease. [Methods] The clinical data of 2 patients with pathological diagnosis of renal medullary carcinoma (RMC) in Zhujiang Hospital during 2019 and 2023 were retrospectively analyzed, and relevant literature was reviewed. [Results] Both patients had symptoms of backache, and imaging examination indicated renal space-occupying lesions.Case 1 was diagnosed as RMC by renal biopsy, and case 2 was pathologically diagnosed as RMC after surgery.Both cases lacked evidence of sickle cell trait or sickle cell disease, and were finally diagnosed as RCCU-MP.Case 1 did not receive antineoplastic therapy and died 5 months after diagnosis.Case 2 underwent laparoscopic nephrectomy, and then received gemcitabine + paclitaxel chemotherapy + immunotherapy.The patient's tumor progressed gradually after first-line treatment was abandoned due to concurrent hematologic infection, and he eventually died 7 months after surgery. [Conclusion] The clinical features of RCCU-MP are partially similar to those of RMC.The diagnosis of RCCU-MP requires pathological examinations and should exclude sickle cell trait or sickle cell disease.Due to the aggressive nature of the tumor, the prognosis of patients is poor.
